• JNK-IN-7 for Apoptosis and MAPK Signaling

  2026-10-01

  Use JNK-IN-7 as a selective JNK inhibitor to separate proximal c-Jun signaling from downstream apoptosis and innate immune phenotypes. Its isoform potency, covalent engagement, and concentration-dependent pathway selectivity support cleaner experiments in fungal infection, inflammatory, and cell-death models.

• SU5416 (Semaxanib): Reliable Assay Design

  2026-10-01

  A scenario-based guide to using SU5416 (Semaxanib), SKU A3847, in VEGF-driven proliferation, viability, and angiogenesis workflows. It addresses solvent control, concentration selection, model interpretation, and practical product-selection criteria using product data and peer-reviewed evidence.

• Carrier-Platin Triggers a Rapid ROS Storm in Cancer Cells

  2026-09-30

  Liu et al. describe carrier-platin, a platinum nanotherapeutic that confines ultrasmall platinum-based nanoparticles within a poly(amino acids) carrier to catalyze rapid intracellular ROS production. The study links this oxidative burst to cancer-cell death that is independent of DNA damage and distinct from canonical apoptosis or ferroptosis, offering a potential strategy against multidrug-resistant tumors.

• Distinct Apoptotic Pathways in C. krusei Mastitis

  2026-09-30

  This study shows that Candida krusei morphology determines how bovine mammary epithelial cells undergo apoptosis: the yeast phase preferentially engages mitochondrial injury, whereas the hypha phase is associated with death ligand/receptor signaling. Its phase-resolved co-culture design links these outcomes to TLR2/ERK and JNK/ERK signaling, providing a useful framework for mechanistic mastitis and apoptosis research.

• Bradford Protein Assay Kit: Practical Guide

  2026-09-29

  The Bradford Protein Assay Kit (K4103) provides a rapid colorimetric method for measuring protein concentration in solution using a Coomassie G-250 reagent and BSA standards. It is appropriate for routine protein quantification in molecular biology, enzyme, and purification workflows, but samples with incompatible detergents, strong alkaline components, turbidity, or concentrations outside the validated range require additional evaluation.

• Chloroquine Pharmacogenomics: Evidence and Implications

  2026-09-29

  The 2023 review by Biswas and Sukasem consolidates evidence that CYP2C8, CYP3A5, CYP2D6, and related metabolic variation may alter chloroquine and hydroxychloroquine exposure, efficacy, and toxicity. Its main contribution is a risk-phenotype framework that connects ultra-rapid and poor metabolizer states with possible therapeutic failure or adverse effects while emphasizing that clinical implementation still requires stronger validation.

• Eldecalcitol, Endothelial Ferroptosis, and T2DOP

  2026-09-28

  A 2025 study identifies endothelial ferroptosis as a mechanistic link between the high-glucose/high-fat environment of type 2 diabetes and impaired bone vascular–osteogenic coupling. Its evidence supports an SOCE/O-GlcNAcylation pathway through which eldecalcitol reduces lipid oxidative injury, improves vascular responses, and preserves osteogenesis in type 2 diabetic osteoporosis models.

• PX-478 Reduced ASD-Like Behaviors After Prenatal Hypoxia

  2026-09-28

  In a prenatal-hypoxia rat model, postnatal PX-478 treatment improved several autism-like behavioral measures and altered hippocampal HIF-1α and PTEN protein levels, alongside lower serum VEGF. The findings connect hypoxia signaling with neurodevelopmental outcomes in this model, but do not establish efficacy in people or prove that the measured molecular changes caused the behavioral effects.

• From Mechanism to Measurement in Diabetic Nephropathy

  2026-09-27

  Phillygenin research highlights how inflammation and apoptosis intersect in diabetic kidney injury. This article examines how membrane-integrity-based fluorescent cell counting can strengthen preclinical interpretation—while clarifying what AO/PI staining can, and cannot, establish.

• CRISPR Screen Maps Brucella Host-Dependency Genes

  2026-09-26

  A genome-wide CRISPR knockout screen in human THP-1 macrophages nominated host genes that influence Brucella infection, with individual knockout validation highlighting TRAPPC2 as a broad restriction point. The findings connect TRAPPC2 deficiency with reduced autophagosome formation, lower macrophage apoptosis, and improved cell viability, while underscoring the need for validation in primary cells and in vivo models.

• Neticonazole Hydrochloride: Bench Workflow Guide

  2026-09-25

  Neticonazole Hydrochloride offers researchers an imidazole antifungal tool for superficial Candida workflows and an exploratory route into colorectal cancer research. This guide separates established topical-treatment context from proposed laboratory workflows, with practical controls for solvent, fungal-growth, and exosome assays.

• ALC-0159 PEG Lipid: Evidence and Use

  2026-09-25

  ALC-0159 is a PEG-conjugated lipid excipient used in lipid nanoparticle formulations for mRNA delivery. Research on membrane-destabilizing zwitterionic lipids reports improved antigen expression and reduced local reactogenicity in mice, but does not establish those effects as properties of ALC-0159 itself.

• Protease Inhibitor Cocktail in Lysosome Research

  2026-09-24

  Learn how a Protease Inhibitor Cocktail EDTA-Free can preserve lysosomal proteins during sample preparation without confusing protein stability with organelle repair. This article connects recent findings on TECPR1-mediated lysosomal membrane tubulation to practical choices for extraction, phosphorylation analysis, and downstream assays.

• Batimastat (BB-94): MMP Assay & Model Workflows

  2026-09-24

  Use Batimastat (BB-94) to probe broad-spectrum MMP activity in enzyme assays, matrix-remodeling studies, and preclinical tumor models. This workflow also outlines a cautious way to test extracellular MMP involvement in localized BDNF processing—without confusing that hypothesis with the reference study’s demonstrated furin-dependent findings.

• Anti Reverse Cap Analog (ARCA): Evidence & Use

  2026-09-23

  Anti Reverse Cap Analog is a Cap 0 in vitro transcription cap analog designed to favor correct-orientation incorporation into synthetic mRNA. Product information reports approximately twofold higher translation efficiency than conventional m7G cap analogs, while the cited oligodendrocyte study supports synthetic mRNA reprogramming—not a direct test of ARCA.

8794 records 3/587 page Previous Next 12345 下5页 Last page